These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20219378)

  • 1. Statistical molecular design of a focused salicylidene acylhydrazide library and multivariate QSAR of inhibition of type III secretion in the Gram-negative bacterium Yersinia.
    Dahlgren MK; Zetterström CE; Gylfe S; Linusson A; Elofsson M
    Bioorg Med Chem; 2010 Apr; 18(7):2686-703. PubMed ID: 20219378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of type III secretion in Yersinia: design, synthesis and multivariate QSAR of 2-arylsulfonylamino-benzanilides.
    Kauppi AM; Andersson CD; Norberg HA; Sundin C; Linusson A; Elofsson M
    Bioorg Med Chem; 2007 Nov; 15(22):6994-7011. PubMed ID: 17851084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of novel polypharmacological antichlamydial agents.
    Sunduru N; Salin O; Gylfe Å; Elofsson M
    Eur J Med Chem; 2015 Aug; 101():595-603. PubMed ID: 26204507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and multivariate quantitative structure-activity relationship of salicylanilides--potent inhibitors of type III secretion in Yersinia.
    Dahlgren MK; Kauppi AM; Olsson IM; Linusson A; Elofsson M
    J Med Chem; 2007 Nov; 50(24):6177-88. PubMed ID: 17975903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle.
    Bailey L; Gylfe A; Sundin C; Muschiol S; Elofsson M; Nordström P; Henriques-Normark B; Lugert R; Waldenström A; Wolf-Watz H; Bergström S
    FEBS Lett; 2007 Feb; 581(4):587-95. PubMed ID: 17257594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-clinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretion.
    Ur-Rehman T; Slepenkin A; Chu H; Blomgren A; Dahlgren MK; Zetterström CE; Peterson EM; Elofsson M; Gylfe A
    J Antibiot (Tokyo); 2012 Aug; 65(8):397-404. PubMed ID: 22669447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Derivatives of 8-hydroxyquinoline--antibacterial agents that target intra- and extracellular Gram-negative pathogens.
    Enquist PA; Gylfe A; Hägglund U; Lindström P; Norberg-Scherman H; Sundin C; Elofsson M
    Bioorg Med Chem Lett; 2012 May; 22(10):3550-3. PubMed ID: 22525317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of bacterial target proteins for the salicylidene acylhydrazide class of virulence-blocking compounds.
    Wang D; Zetterström CE; Gabrielsen M; Beckham KS; Tree JJ; Macdonald SE; Byron O; Mitchell TJ; Gally DL; Herzyk P; Mahajan A; Uvell H; Burchmore R; Smith BO; Elofsson M; Roe AJ
    J Biol Chem; 2011 Aug; 286(34):29922-31. PubMed ID: 21724850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
    Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
    J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model.
    Garrity-Ryan LK; Kim OK; Balada-Llasat JM; Bartlett VJ; Verma AK; Fisher ML; Castillo C; Songsungthong W; Tanaka SK; Levy SB; Mecsas J; Alekshun MN
    Infect Immun; 2010 Nov; 78(11):4683-90. PubMed ID: 20823209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diacylhydrazine derivatives as novel potential chitin biosynthesis inhibitors: design, synthesis, and structure-activity relationship.
    Ke S; Qian X; Liu F; Wang N; Fan F; Li Z; Yang Q
    Eur J Med Chem; 2009 Jul; 44(7):2985-93. PubMed ID: 19216009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biosynthesis and biological role of 6-deoxyheptose in the lipopolysaccharide O-antigen of Yersinia pseudotuberculosis.
    Ho N; Kondakova AN; Knirel YA; Creuzenet C
    Mol Microbiol; 2008 Apr; 68(2):424-47. PubMed ID: 18284593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased virulence of Yersinia pseudotuberculosis by two independent mutations.
    Rosqvist R; Skurnik M; Wolf-Watz H
    Nature; 1988 Aug; 334(6182):522-4. PubMed ID: 3043229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The resveratrol tetramer (-)-hopeaphenol inhibits type III secretion in the gram-negative pathogens Yersinia pseudotuberculosis and Pseudomonas aeruginosa.
    Zetterström CE; Hasselgren J; Salin O; Davis RA; Quinn RJ; Sundin C; Elofsson M
    PLoS One; 2013; 8(12):e81969. PubMed ID: 24324737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria.
    Keyser P; Elofsson M; Rosell S; Wolf-Watz H
    J Intern Med; 2008 Jul; 264(1):17-29. PubMed ID: 18393958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in hemG mediate resistance to salicylidene acylhydrazides, demonstrating a novel link between protoporphyrinogen oxidase (HemG) and Chlamydia trachomatis infectivity.
    Engström P; Nguyen BD; Normark J; Nilsson I; Bastidas RJ; Gylfe A; Elofsson M; Fields KA; Valdivia RH; Wolf-Watz H; Bergström S
    J Bacteriol; 2013 Sep; 195(18):4221-30. PubMed ID: 23852872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LcrV synthesis is altered by DNA adenine methylase overproduction in Yersinia pseudotuberculosis and is required to confer immunity in vaccinated hosts.
    Badie G; Heithoff DM; Mahan MJ
    Infect Immun; 2004 Nov; 72(11):6707-10. PubMed ID: 15501808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of Yersinia Yop-effector delivery by translocated YopE.
    Aili M; Isaksson EL; Carlsson SE; Wolf-Watz H; Rosqvist R; Francis MS
    Int J Med Microbiol; 2008 Apr; 298(3-4):183-92. PubMed ID: 17597003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A comparative study of the role of the yadA, invA, and psaA genes in the pathogenicity of Yersinia pseudotuberculosis].
    Karataev GI; Markov AR; Siniashina LN; Miller GG; Klitsunova NV; Titova IV; Semin EG; Goncharova NI; Pokrovskaia MS; Amelina IP; Amoako K; Smirnov GB
    Mol Gen Mikrobiol Virusol; 2008; (4):10-8. PubMed ID: 19172873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds.
    Shen M; Béguin C; Golbraikh A; Stables JP; Kohn H; Tropsha A
    J Med Chem; 2004 Apr; 47(9):2356-64. PubMed ID: 15084134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.